Bulletin du cancer (B CANCER)

Publications in this journal

• Article: Ubiquitine, protéasome et cancer

  Delcros JG, Arlot-Bonnemains Y
  Bulletin du cancer 04/2006; 93.
• Article: Role of non invasive animal imaging in preclinical anticancer drug development.

  Guilbaud N, Duchamp O, Just N, Genne P
  Bulletin du cancer 01/2005; 92(1):45-57.
• Article: Diffuse medulla oblongata and pontine gliomas in childhood. A review of 37 cases.

  Christian Carrie, Sylvie Negrier, Frédéric Gomez, Philippe Thiesse, Carmine Mottolese, Didier Frappaz, Eric Bouffet
  [show abstract] [hide abstract]
  ABSTRACT: From 1975 to 1997, thirty seven newly diagnosed children aged 2 mos. to 14.3 years with diffuse medulla oblongata or pontine tumours were referred to the Centre Léon Bérard. Surgical biopsies were performed in 9 patients. All but one received radiation therapy. The mean dose of radiation was 53 Gy. Thirty two received chemotherapy. All patients died, one from related toxicity, and the rest from progressive disease. Relapses always occurred in the radiotherapy field. Medulla oblongata and pontine tumours would appear to have the worst outcome of all brain stem gliomas and should be separately analysed.
  Bulletin du cancer 07/2004; 91(6):E167-83.
• Article: Stochastic modeling of the tumor volume assessment and growth patterns in hepatocellular carcinoma.

  Adrian Sãftoiu, Tudorel Ciurea, Florin Gorunescu, Ion Rogoveanu, Claudia Georgescu
  [show abstract] [hide abstract]
  ABSTRACT: The growth pattern of hepatocellular carcinoma (HCC) arising from cirrhosis is variable and depends on the degree of differentiation and vascularization. Because growth is not constant in the natural history of HCC, prediction of subsequent growth rate based on tumor volume doubling time and correlation with histological and ultrasonographical characteristics at the moment of initial diagnosis are usually unreliable. The aim of our study was to assess the growth patterns of HCC with the aid of stochastic modeling. Thus, we included in our study 27 patients with histologically proven HCC, which had multiple (more than three)follow-up ultrasound studies in a six months interval. The patients did not receive any treatment during the observation period. HCC was visualized by computer aided ultrasound imaging, obtaining both the primary size quantification and the edge-detection enhancement. By a bi-cubic B-spline interpolation of points on the edges (3-D Bezier approximation) we approximated the surfaces shapes, and using the hit or miss Monte Carlo method we accurately estimate the tumor volume. Starting from the previous tumor volumes time series recorded during the first six months of evolution we applied both a linear, exponential and logarithmic smoothing to forecast the future size of the HCC tumor in the next six months. Our conclusion was that a dynamic forecasting model of HCC volumes could be very accurate for the assessment of tumor volume doubling time usually obtained by two discrete volume measurements of the tumor.
  Bulletin du cancer 07/2004; 91(6):E162-6.
• Article: Does the primary Lung Cancer rate increase among females?

  Oguzhan Okutan, Zafer Kartaloglu, Ahmet Ilvan, Erdogan Kunter, Kamil Cerrahoglu, Firuz Capraz
  [show abstract] [hide abstract]
  ABSTRACT: Lung cancer is still the most frequently seen malignancy among males where as females are less affected. Recently the lung cancer prevalence has been reported to increase among females in parallel to the increment in cigarette consumption. In our 2 clinic 11.2% (44 cases) of 393 primary lung cancer cases between 1993-1997 were female. We evaluated the demographical characteristics and yearly distribution of our female patients. Mean age was 64+/-12.1 and 18.2% of the patients were smokers. The main complaints were dyspnoea (59%), chest pain (57%), fatigue (47%), cough (45%)and sputum production (32%). The cell type distribution rates were as follows;adenocarcinoma 45.4%, squamous cell cancer 29.5%, small cell cancer 20.5% and large cell cancer 4.6%. The diagnostic methods used were sputum cytology (27.3%),transbronchial biopsy and lavage (38.6%), thoracocentesis and pleural biopsy (15.8%),transthoracic fine needle aspiration (13,6%) and open lung biopsy (4.7%). As a result,we found a low percentage of smokers but a high rate of adenocarcinomas among our female patients.
  Bulletin du cancer 07/2004; 91(6):E201-10.
• Article: Homophilic anchorage of brain-hexokinase to mitochondria-porins revealed by specific-peptide antibody cross recognition.

  Stéphane Oudard, Laurent Miccoli, Arnaud Beurdeley-Thomas, Bernard Dutrillaux, Marìe-France Poupon
  [show abstract] [hide abstract]
  ABSTRACT: In brain tumors the main source of energy is from glycolysis, which is initiated by hexokinase 1 (HK1), an enzyme bound to the mitochondrial porin. Disruption of HK binding greatly affects tumor cell survival. Little is known about the acceptor site of HK1. Therefore, a polyclonal antibody (Pab) directed to MIAAQLLAYYFTELK (MK) peptide, corresponding to the 15-amino acids of the N-terminal sequence of brain HK1 was obtained. Anti MK antibody (aMK-Pab)bound specifically to HK as shown by ELISA. The aMK-Pab binding to MK peptide was antibody-concentration dependent and was completely abolished by its preincubation with the peptide at 6 x 10-8 M. The aMK-Pab recognized cytosolic HK (cHK) and HK solubilized (sHK)from rat-brain mitochondrial preparations, but not the yeast HK which does not have the MK sequence. An anti-brain HK Pab (aHK-Pab) directed to purified HK recognized the MK peptide; aHK-Pab bound to MK and this binding was inhibited by preincubation of the antibody with the MK peptide. It was previously demonstrated that brain HK anchors to mitochondria porins, also designated as voltage dependent-anion channels (VDAC) via the MK sequence. A specific anti-VDAC antibody (aVDAC-Pab) which specifically bound the N and C-terminal sequences of VDACwas found to bind to c-HK, sHK and MK-coated wells and this binding was abolished by aVDACPabpreincubation with MK peptide. These data suggest that the three Pabs cross-react with an epitope present in HK and VDAC, and which was presented in the MK peptide. Comparison of alignment of HK or VDAC sequences, available in the protein data bank (PDB), did not allow putative homologues responsible for the cross-reaction to be identified, suggesting that the epitope is conformational. This, added to inhibition of mitochondria-isolated HK binding by the MK peptide,suggests that there is an homophilic-type interaction between HK and porin, through a peptidic structure represented at least in part in the MK peptide.
  Bulletin du cancer 07/2004; 91(6):E184-200.
• Article: Comparison between hospitalized and screening controls in studies assessing breast cancer risk.

  Samantha Garbers, Neil Dubin, Paolo Toniolo, E L Wynder, Emanuela Taioli
  [show abstract] [hide abstract]
  ABSTRACT: In case-control studies, selection of an appropriate group of controls is a critical step which may affect the outcome of the analysis. We studied the differences in reproductive, lifestyle, and anthropometric variables between controls from a hospital-based study and controls from a screening clinic. Odds ratios for breast cancer were calculated using the two types of controls, and the impact on the resulting odds ratio was studied. Some interesting differences in odds ratios obtained with the two sets of controls were found. Among premenopausal screening subjects, the odds ratio for breast cancer did not change across quartiles of body mass,while among hospital subjects, the risk of breast cancer significantly decreased with increasing body mass. For liquor and beer consumption, a three-fold increase in breast cancer risk was observed among premenopausal hospital subjects, whereas no association was found among screening subjects. Among postmenopausal women, a significant decrease in breast cancer risk with ovariectomy was only observed in the hospital-based study. Our results suggest that in examining the association between body mass, alcohol consumption, or ovariectomy and breast cancer risk, the choice of control group used should be carefully considered.
  Bulletin du cancer 07/2004; 91(6):E211-24.
• Article: [Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials].

  Jean-Paul Guastalla, Thomas Bachelot, Isabelle Ray-Coquard
  [show abstract] [hide abstract]
  ABSTRACT: Cyclooxygenases (Cox) are prostaglandin synthetase enzymes which play a key role in mammary carcinogenesis. Several connections were demonstrated between Cox and a few oncogenes (v-src, v-Ha-ras, HER-2/neu, Wnt, p53 mutated), alimentary products (PUFAs), transcription factors (c-jun and c-fos), proapoptotic proteins [Bax et Bcl-x(L)] or antiapoptotic (Bcl-2), CYP19 aromatase gene, NFkappaB receptor (RANKL), angiogenesis (via VEGF, TXA2, oxid nitric synthetase, alphaVbeta3 integrin receptor), peroxisome gamma proliferator receptor (PPARgamma) and its ligand PGJ2 and with antitubuline chemotherapy drugs. No correlation of Cox2 expression with hormonal receptors was shown. In epidemiologic studies there is evidence of breast cancer risk reduction for women who take AINS for a long time. Alimentary factors like resveratrol or insaturated fat acid reduce Cox2 expression in animal and could be investigated in human studies. Clinical trials are planed with the anti Cox2 celecoxib for breast cancer prevention, in adjuvant setting, in metastatic situation combined with exemestane or antitubulin drugs or in neoadjuvant therapy.
  Bulletin du cancer 06/2004; 91 Spec No:S99-108.
• Article: [Management of emesis in cancer patients].

  Khemaies Slimane, Adriana Perez, Pierre Ruffié, Mario di Palma
  [show abstract] [hide abstract]
  ABSTRACT: Nausea and vomiting are often seen in cancer patients. They can be acute (induced by chemotherapy or radiotherapy...), or chronic in patients with advanced disease. A high percentage of patients (70% to 80%) suffer from chemotherapy induced nausea and vomiting. The incidence and severity of these symptoms depend of the nature of chemotherapy, doses, other drugs used in association, and psychological status of the patients. International guidelines have improved the management of nausea and vomiting, with the use of new drugs like setrons. Despite this, optimal care of refractory and delayed nausea and vomiting after chemotherapy is still a matter of debate. Chronic nausea and vomiting concern more than 50% of patients in palliative situation. The origin is often multifactorial. Management consists in aetiologic and symptomatic treatment in order to improve the patients' quality of life.
  Bulletin du cancer 06/2004; 91(5):403-8.
• Article: [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].

  Dominique Lamarque
  [show abstract] [hide abstract]
  ABSTRACT: The serious digestive side effects of the selective inhibitors the inducible cyclooxygenase-2 are reduced by 60% as compared to the nonselective non-steroidal anti-inflammatory drugs. The main risk factors associated with gastro-intestinal ulcers caused by the latter were found also with the selective inhibitors taken for long period (age > 60 years, antecedents of gastro-duodenal ulcers, concomitant aspirin treatment). In contrast, H. pylori infection was not found as risk factor apart from past history of gastro-duodenal ulcers. The complications in the lower digestive tract are twice less frequent with the selective inhibitors than with nonselective anti-inflammatory drugs. Nevertheless, it seems that the risk of exacerbation of inflammatory colitis is not reduced. The cardiovascular complications are discussed. Rofecoxib taken at supra-therapeutic dosage was recognised to increase the incidence of myocardial infarction. A such increase was not found with usual dosage or with celecoxib. The selective inhibitors may reduce the renal sodium excretion and increase the blood pressure, particularly in hypertensive patients whose the blood pressure has to be regularly checked.
  Bulletin du cancer 06/2004; 91 Spec No:S117-24.
• Article: [For a coordination of the supportive care for people affected by severe illnesses: proposition of organization in the public and private health care centres].

  Ivan Krakowski, François Boureau, Roland Bugat, Laurent Chassignol, Philippe Colombat, Laure Copel, Daniel d'Hérouville, Marylène Filbet, Bernard Laurent, Nadine Memran, Jacques Meynadier, Gérard Parmentier, Philippe Poulain, Pierre Saltel, Daniel Serin, Jean-Philippe Wagner
  [show abstract] [hide abstract]
  ABSTRACT: The concept of continuous and global care is acknowledged today by all as inherent to modern medicine. A working group gathered to propose models for the coordination of supportive care for all severe illnesses in the various private and public health care centres. The supportive care are defined as: "all care and supports necessary for ill people, at the same time as specific treatments, along all severe illnesses". This definition is inspired by that of "supportive care" given in 1990 by the MASCC (Multinational Association for Supportive Care in Cancer): "The total medical, nursing and psychosocial help which the patients need besides the specific treatment". It integrates as much the field of cure with possible after-effects as that of palliative care, the definition of which is clarified (initial and terminal palliative phases). Such a coordination is justified by the pluridisciplinarity and hyperspecialisation of the professionals, by a poor communication between the teams, by the administrative difficulties encountered by the teams participating in the supportive care. The working group insists on the fact that the supportive care is not a new speciality. He proposes the creation of units. departments or pole of responsibility of supportive care with a "basic coordination" involving the activities of chronic pain, palliative care, psycho-oncology, and social care. This coordination can be extended, according to the "history" and missions of health care centres. Service done with the implementation of a "unique counter" for the patients and the teams is an important point. The structure has to comply with the terms and conditions of contract (Consultation, Unit or Centre of chronic pain, structures of palliative care, of psycho-oncology, of nutrition, of social care). A common technical organization is one of the interests. The structure has to set up strong links with the private practitioners, the networks, the home medical care (HAD) and the nurses services at home (SSIAD), when they exist, to guarantee the continuity of the supportive care under all its aspects and in order to take into account the preferences of the patients. According to Hospital 2007 propositions, the extended, flexible and general purpose Group of Sanitary Cooperation (GCS) meets the necessities inherent to the structures of supportive care within the territories of health because it can be established between one or several health care centres and the private health professionals, thus favouring the cooperation between public and private health care centres. PSPH and general medicine.
  Bulletin du cancer 06/2004; 91(5):449-56.
• Article: [Anticancer drugs use evaluation: limits of the approved labeling].

  Isabelle Debrix, Thierry André, Antoine Flahault, Ogbe Kalu, Joseph Gligorov, Jean-Pierre Lotz, Bernard Milleron, Françoise Pene, Yasmine Boukari, Annie Becker
  [show abstract] [hide abstract]
  ABSTRACT: A practice survey was performed in Tenon hospital on 396 consecutive patients treated for solid tumors during 4 weeks in november 2002. 33% of anticancer drugs were off label used. The wording heterogeneity of the different anticancer drugs approved labeling and the lack of anticancer drugs in a number of cancers can explain those results. On one hand, randomised comparative clinical trial, considered as the best level of evidence to obtain a label used, is not always possible in cancerology, especially for rare tumors. One the other hand, pharmaceutical firm are not obliged to asked a label used for an anticancer drugs in spite of high level of evidence. So, label used can not be the own references for anticancer drugs prescribing, therapeutic advanced can be realised and disseminated before their taking into account in the label used.
  Bulletin du cancer 06/2004; 91(5):437-43.
• Article: [A prospective evaluation of antibiotic prophylaxis efficacy for breast cancer surgery following previous chemotherapy].

  Nicolas Penel, Charles Fournier, Sylvia Giard, Danièle Lefebvres
  [show abstract] [hide abstract]
  ABSTRACT: Use of antibiotic prophylaxis (AP) in clean breast cancer surgery is still controversial. We assessed the efficacy of preoperative AP in a prospective study of 171 clean breast cancer procedures following previous anticancer chemotherapy. From June 1998 to July 2001, we analyzed 171 procedures. In 133 cases. AB with cefuroxime was performed. Wound infection rate was 3 out of 171 procedures (WI rate of 2/131 with AP compared with 1/37 without AP, p = 1.0). This study suggests that AP is not systematically required in breast cancer surgery following previous anticancer chemotherapy.
  Bulletin du cancer 06/2004; 91(5):445-8.
• Article: [pRB, p53, p16INK4a, senescence and malignant transformation].

  Christian-Jacques Larsen
  [show abstract] [hide abstract]
  ABSTRACT: Recent works aimed at clarifying the respective roles of p16INKa and p14ARF (both located on the same INK4a locus on chromosome 9p21 in man) in malignant transformation come to the conclusion that p16INK4a is the true tumor suppressor gene in man. In mouse, it is the p19ARF knockout that suppresses the barrier protecting cells from malignant transformation. This situation is in agreement with p19ARF- and p16-mediated senescence induced by oncogenic mutated ras (Ras*) in mouse and man respectively. Other results have shown that senescence in human diploid fibroblasts is associated with heterochromatin occurrence that maintains in repressed state E2F1-induced gens required for G1 to S phases transition. Since RB protein is responsible for this chromatin modification, cells with any impaired RB pathway cannot enter into senescence.
  Bulletin du cancer 06/2004; 91(5):399-402.
• Article: [Cancer prevention: congress report].

  Gilles L'Allemain
  Bulletin du cancer 06/2004; 91(5):457-9.
• Article: [2003 clinical practice guideline: Standards, Options and Recommendations for pain assessment in adult and children with cancer (summary report)].

  Thierry Delorme, Chantal Wood, Anne Bartaillard, Evelyne Pichard, Sarah Dauchy, Daniel Orbach, Jean-Pierre Alibeu, Christine Ricard, Agnès Suc, François Boureau, Sophie Roiusmans, Régis Patte, Nicole Vullemin, Gérard Torloting, François Larue, Jean-Michel Lassauniere, Elisabeth Collin
  [show abstract] [hide abstract]
  ABSTRACT: The "Standards, Options and Recommendations" (SOR) project, which started in 1993, is a collaboration between the French Federation of Cancer Centers (FNCLCC), the 20 French Regional Cancer Centers, and specialists from French public universities, general hospitals and private clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients. To update clinical practice guidelines for the assessment of pain in adult or children with cancer in collaboration with the French society for pain study and treatment. The methodology is based on a literature review and critical appraisal by a multidisciplinary group of experts who define the CPGs according to the definitions of the Standards, Options and Recommendations project. Once the guideline has been defined, the document is submitted for review by independent reviewers. This article is a summary version of the full document presenting the clinical practice guidelines with algorithms. The main recommendations concern the means used to evaluate pain and its consequences and their use in specific cases (acute or chronic pain, patients able to communicate or not, children under or over 6 years old). Others recommendations were also established concerning the evaluation ofpsychological, social and family context, the evaluation of pain in hospital or at home, in terminal phase patients and for the establishment of a therapeutic strategy and follow-up of patient with pain.
  Bulletin du cancer 06/2004; 91(5):419-30.
• Article: Treatment of peritoneal carcinomatosis in patients with digestive cancers with combination of intraperitoneal hyperthermia and mitomycin C.

  Annie C Sayag-Beaujard, Yves Francois, Olivier Glehen, Babak Sadeghi-Looyeh, Jacques Bienvenu, Gilles Panteix, Florence Garbit, Eric Grandclément, Vincent Banssillon, Jacques Vignal, François N Gilly
  [show abstract] [hide abstract]
  ABSTRACT: Peritoneal carcinomatosis in patients with digestive cancer carries a poor prognosis, with a majority of patients dying within 6 months. Mitomycin C has been reported to have some antitumor efficacy in this setting. We performed combination intraperitoneal hyperthermia and mitomycin to potentiate the effect of mitomycin C in 83 patients with peritoneal involvement due to digestive cancers. Eighty six IPCH procedures were performed using inflow temperature 46 to 49 degrees Celsius, using a closed circuit, during 90 minutes. Mitomycin C was administered as a perfusate at 10 mg/l. Primary tumors were essentially gastric (42) and colorectal (27). Mortality and morbidity rates were 3/83 and 5/83 respectively. For resectable tumors, the median survival time was 16 months in stage 1 and 2 carcinomatosis (malignant granulations less than 5 mm in diameter). For resectable gastric cancers with stage 1 and 2 carcinomatosis, one, two and three year actuarial survival rates were 80, 61 and 41% respectively. In conclusion, IPCH appears to be an interesting therapeutic option in patients with digestive cancers and small malignant peritoneal granulations (stage 1 and 2).
  Bulletin du cancer 06/2004; 91(5):E113-32.